Page 13 - Aurobindo Pharma

Aurobindo Pharma dips on USFDA procedural observations on Hyderabad unit

The stock dipped 4.7% to Rs 633 on BSE in late noon deal.

Aurobindo Pharma gets USFDA nod for HIV treatment drug

The stock of Aurobindo Pharma was trading 0.98 per cent higher at Rs 678 on the BSE

USFDA gives final nod for Aurobindo's Meropenem anti-bacterial injection

BS Reporter Hyderabad, 28 MarchAurobindo Pharma has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Meropenem injection, which is used in the treatment of complicated skin and other bacterial infections. Meropenem injection 500 mg/vial and 1 g/vial will be launched next month. This is a generic version of AstraZeneca Pharmaceuticals' Merrem Injection. It is indicated as single agent therapy for skin infections, complicated intra-abdominal infections such as appendicitis and peritonitis, and bacterial meningitis, the company said in a statement.According to IMS, Meropenem has an estimated market size of $118 million for the twelve months ending January 2017. This is the first abbreviated new drug application (ANDA) approved out of its subsidiary Auronext Pharma's formulation facility in Bhiwadi. This unit is used for manufacturing penem injectable products. With this, the Hyderabad-based company has an overall 314 ANDA approvals ...

US court favours Aurobindo in patent case on cough & cold drug

The court has scheduled a five-day bench trial beginning April 17 to deliver a final judgment

Aurobindo Pharma's Reddy transfers holding to trustee company

FM Arun Jaitley has imposed a 10% tax on dividend income on shares held by trusts

Aurobindo Pharma eyes US plant as Trump's 'border tax' hangs fire

Aurobindo reported a lower-than-expected October-December profit on Friday

Aurobindo acquires four biosimilar products under development

They were acquired from TL Biopharmaceutical AG of Switzerland

Aurobindo Q3 net rises 6% to Rs 578 cr

The total income of the company increased 11% to Rs 3,906 cr

Aurobindo aims for top-5 position in Europe

Firm eyes Euro 1 bn revenue in the continent, seeks to hike market share to 3% from 2% currently

Aurobindo strengthens its presence in Europe

The Portuguese acquisition should rub off positively on the stock

Aurobindo buys Portuguese firm for Rs 963 crore

To become leader in Portugal's generic drugs market

Aurobindo Pharma to buy Portugal-based Generis for Rs 969 cr

Acquisition includes Generis' facility in Amadora which can manufacture 1.2 bn tablets annually

Compass: Concerns overdone on Aurobindo Pharma

FDA observations, lawsuit impact to be negligible while earnings momentum is expected to continue

Aurobindo Pharma Unit 1 gets US FDA observations

The plant is used for manufacturing of active pharmaceutical ingredients

Aurobindo pharma to acquire select products in France from Teva

Both companies intend to ensure continuity of the supply of the products to the market

Improving margin to up Aurobindo earnings

Even as revenue growth may soften due to high base, rising operating profit margin bodes well for firm

Aurobindo Pharma Q2 net profit up 33% at Rs 605 crore

Company's income from operations grew 12.19% to Rs 3775.45 crore

US FDA gives tentative approval for Aurobindo's generic HIV drug

ViiV Healthcare, Aurobindo Pharma signed an agreement allowing Aurobindo to supply Dolutegravir 50 mg in 92 licensed countries

Aurobindo Pharma gains on tentative nod for HIV drug

The stock up 4% to Rs 842 after the company has received the tentative approval of Dolutegravir 50mg from USFDA for the treatment of HIV.

Aurobindo Pharma plans to launch 19 drugs in US in next 3 quarters

The company has already 20 products in the US market under OTC segment